Legend Biotech (LEGN) Return on Capital Employed (2020 - 2026)
Legend Biotech's (LEGN) quarterly Return on Capital Employed came in at 15.41% in Q1 2026, up 918.0% YoY from 1.51% in Q1 2025, and down 4.97% on a QoQ basis from 16.21% in Q4 2025.
Legend Biotech (LEGN) Return on Capital Employed (2020 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 7 years of Return on Capital Employed data on file, last reported at 15.41% in Q1 2026.
- Quarterly Return on Capital Employed rose 918.0% year-over-year to 15.41% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.41% (up 918.0% YoY) and the FY2025 annual result came in at 12.81%, up 808.0% from the prior year.
- Return on Capital Employed declined to 15.41% in Q1 2026, from 16.21% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 5365.73% in Q2 2024 to a low of 48.97% in Q1 2022.
- A 5-year average of 1488.57% and a median of 19.24% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 532819 bps — and 2025, when it slumped 535926 bps.
- Tracing LEGN's Return on Capital Employed over 5 years: stood at 48.97% in 2022, then surged by 10122 bps to 4907.99% in 2023, then sank by 100 bps to 22.26% in 2024, then declined by 27 bps to 16.21% in 2025, then decreased by 5 bps to 15.41% in 2026.
- The last three Return on Capital Employed figures came in at 15.41% (Q1 2026), 16.21% (Q4 2025), and 9.2% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | -4.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.35% |
| Mar 31, 2026 | 15.41% |
| Dec 31, 2025 | 16.21% |
| Sep 30, 2025 | 9.20% |
| Jun 30, 2025 | 6.47% |
| Mar 31, 2025 | 6.23% |
| Dec 31, 2024 | 22.26% |
| Sep 30, 2024 | 5,335.72% |
| Jun 30, 2024 | 5,365.73% |
| Mar 31, 2024 | 5,117.85% |
| Dec 31, 2023 | 4,907.99% |
| Sep 30, 2023 | 32.79% |
| Jun 30, 2023 | 37.54% |
| Mar 31, 2023 | 15.53% |
| Mar 31, 2022 | -48.97% |
| Dec 31, 2021 | -52.38% |
| Sep 30, 2021 | -62.40% |
| Jun 30, 2021 | -0.10% |
| Mar 31, 2021 | -0.08% |
| Dec 31, 2020 | -0.09% |